Enovis (NYSE:ENOV) Stock Rating Raised to Buy at Wall Street Zen

Posted by Geri Gentry on Sep 29th, 2026

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV – Free Report) from a hold rating to a buy rating in a report released on Monday morning,Wall Street Zen reports.

Several other research analysts have also recently weighed in on the stock. Wells Fargo & Company cut their price target on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, September 2nd. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Citigroup reissued a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Citizens Jmp decreased their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Finally, UBS Group reissued a “buy” rating and issued a $51.00 price target (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.38.

Check Out Our Latest Report on Enovis

Enovis Stock Down 1.4%

ENOV stock opened at $18.20 on Monday. The firm has a market capitalization of $1.05 billion, a PE ratio of -0.95 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a twelve month low of $17.30 and a twelve month high of $34.28. The stock’s 50 day moving average is $23.57 and its 200-day moving average is $23.61.

Enovis (NYSE:ENOV – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.Enovis’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis will post 3.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The shares were purchased at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares in the company, valued at $4,731,524.55. This represents a 5.57% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Oliver Engert purchased 2,660 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were purchased at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the transaction, the insider directly owned 63,898 shares in the company, valued at approximately $1,201,282.40. The trade was a 4.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 23,293 shares of company stock valued at $449,599 over the last three months. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Several institutional investors have recently added to or reduced their stakes in ENOV. IFP Advisors Inc lifted its position in shares of Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after acquiring an additional 1,174 shares in the last quarter. Allworth Financial LP bought a new position in shares of Enovis in the second quarter worth $36,000. Integrated Wealth Concepts LLC purchased a new position in shares of Enovis in the second quarter valued at $39,000. Public Employees Retirement System of Ohio purchased a new position in shares of Enovis in the second quarter valued at $48,000. Finally, Annis Gardner Whiting Capital Advisors LLC raised its stake in shares of Enovis by 468,400.0% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company’s stock valued at $107,000 after purchasing an additional 4,684 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Company Profile

(Get Free Report)

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.